GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Adherium Ltd (ASX:ADRDA) » Definitions » Total Receivables

Adherium (ASX:ADRDA) Total Receivables : A$2.25 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Adherium Total Receivables?

Adherium's Total Receivables for the quarter that ended in Dec. 2023 was A$2.25 Mil.


Adherium Total Receivables Historical Data

The historical data trend for Adherium's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adherium Total Receivables Chart

Adherium Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Receivables
Get a 7-Day Free Trial 0.44 0.62 0.57 0.42 1.97

Adherium Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.42 0.61 1.97 2.25

Adherium Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Adherium Total Receivables Related Terms

Thank you for viewing the detailed overview of Adherium's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Adherium (ASX:ADRDA) Business Description

Traded in Other Exchanges
N/A
Address
333 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Adherium Ltd is engaged in the development, manufacture, and supply of its Hailie digital health technologies that address sub-optimal medication use and improve health outcomes in chronic disease. Geographically, it derives a majority of its revenue from Europe and also has a presence in New Zealand and Australia; North America, and Asia.

Adherium (ASX:ADRDA) Headlines

No Headlines